Affymetrix and Empire Genomics Enter Into Licensing Agreement
Affymetrix Inc. announced that Empire genomics, LLC, has obtained a non-exclusive, worldwide license to a number of Affymetrix patents covering the manufacturing, use and sales of nucleic acid microarrays and related products and services for comparative genomic hybridization (CGH). The arrays and services may be used for research or diagnostic purposes. Financial details of the license were not disclosed.
"This agreement with Affymetrix enables Empire Genomics to bring its innovative genomics platform to market while continuing the advancement of personalized medicine. We fully expect that focusing in the field of copy number variation will lead to the discovery of the genomic causes of multiple diseases, as well as advanced therapeutic treatment strategies," said Anthony Johnson, president and CEO of Empire Genomics.
Most read news
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Fondant under the magnifying glass - New insights into the properties of sweet coating: The results could be used to optimize the industrial production process in the future
Inflammatory messenger fuels Alzheimer’s - Combination therapy could potentially slow down the deterioration of the brain
Lab21 launches cancer gene testing service
Team tracks real-time molecular motions - Important new insights into a key process for the development of more efficient solar cells
Freeman Technology celebrates 2012 Queen’s Award success